NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Quell Therapeutics

Quell Therapeutics

Private
LondonHealthcare & Life Scienceshttps://www.quell-tx.com/

Last Round

Strategic

Jun 9, 2023

Est. Valuation

$34.09M

Total Funding Raised

$405.4M

Company Overview

Quell Therapeutics is a biotechnology company that develops engineered T-regulatory (Treg) cell therapies to treat severe immune-mediated and inflammatory diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

T-regulatory cell therapyTreg therapyCAR-Tregcell therapyimmunotherapyautoimmune disease treatmentorgan transplant rejectionautologous cell therapybiotechnologydrug developmentclinical trialsprecision medicinenext-gen cell therapy

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Quell Therapeutics Comparables

Compare Quell Therapeutics with similar companies based on industry and business-model similarity.

Quell Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Sonoma Biotherapeutics
88%
GentiBio
84%
ActiTrexx GmbH
83%

Quell Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
StrategicJun 9, 2023
Series BNov 29, 2021
Series A ExtensionFeb 11, 2021
Series AMay 20, 2019
Series AMar 29, 2019

Quell Therapeutics Investors

Notable investors and investment history

Quell Therapeutics investors
InvestorRounds
Janus Henderson GroupSeries B
SV Health InvestorsSeries B
SynconaSeries B, Series A, Series A Extension
Ridgeback CapitalSeries B
Future FundSeries B
Fidelity Management & Research CompanySeries B
British Patient CapitalSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Oct 25, 2025

    Presenting data at ACR Convergence 2025.

  • Oct 25, 2025

    Will present data for QEL-005 CAR-Treg cell therapy at ACR Convergence 2025.

Quell Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Quell Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Quell Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersLondon
Employee Range116
Year Founded2019
Last FundingJun 9, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.